Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Nagel, Jonas Binder, Michael Sztucki, Wolfgang Friess, Tim Menzen, Gerhard Winter, Evgenyi Shalaev #Pharmaceuticals #ProteinStability #FreezeDrying #SAXS #Biophysics #OpenScience To view or add a comment, sign in In the phase 3 ACHIEVE clinical trial, Eli Lilly's orforglipron (an oral glucagon-like peptide 1 [GLP-1] receptor agonist) outperformed semaglutide in lowering A1C levels and promoting weight loss over 52 weeks
*When a person eats, GLP-1 signals to the brain that they are full*
Ci thin sc t da ton thn c trng mn t nhin, lm u mu da, phc hi da chy nng v lm gim cc m thm sm trong thi gian ngn
But unlike insulin, they dont cause weight gain or carry a significant risk of dangerously low blood sugar. Second, GLP-1 medications are showing excellent results for weight management
.webp)
